Company makes notable progress toward 2030+ ESG commitments,
addressing energy, water and waste reduction, environmental impact
of product portfolio and supplier diversification
FRANKLIN
LAKES, N.J., July 5, 2022
/PRNewswire/ -- BD (Becton, Dickinson and Company)
(NYSE: BDX), a leading global medical technology
company, today issued its Fiscal Year 2021 Environmental, Social
and Governance (ESG) Report that details ongoing
efforts that impact company health, human health, community health
and planet health.
"We are taking action to address the most relevant ESG issues
for our business and stakeholders, including climate change,
diversity, pay equity, transparency and reducing the impact our
products have on the environment," said Tom
Polen, chairman, chief executive officer and president of
BD. "We've made commitments that build on our purpose of advancing
the world of health, and true to our culture, we're delivering on
those commitments and positioning BD for sustainable growth and
resilience."
The report includes the first performance measurements and
progress made toward the company's 2030+ ESG commitments, which
were unveiled in October 2021.
Focusing on key areas where the company looks to create meaningful,
measurable change over the next decade, highlights and
achievements from this year's report include:
- Climate change – BD joined the Race to Zero, committing
to scope 1, 2 and 3 greenhouse gas reduction targets in line with
1.5⁰C emissions scenarios to reach science-based net zero emissions
by 2050. The company continues to make progress toward its goal of
25% energy reduction by 2030 (from a 2019 baseline, normalized to
cost of products sold), achieving 14% energy reduction in FY 2021,
in addition to increasing its investment in on-site renewable
energy. Currently, 13 BD locations obtain 100% of their electric
power from renewable sources.
- Product impact – BD recently launched a Sustainable
Medical Technology Institute to help further reduce the
environmental impact of the company's portfolio, set sustainable
design standards for products and identify more sustainable
sterilization technologies. The company continues to manage
end-of-life disposal of products from the BD Pyxis™ portfolio,
resulting in 20,771 units processed in FY 2021, which equates to
1,855.15 metric tonnes of material that was refurbished, reused or
recycled, with no materials disposed of via landfill.
- Responsible supply chain – The company spent
$565 million with diverse-owned
business suppliers and $1 billion
with small business suppliers, impacting 2,766 suppliers in total.
This reflects an average 33% increase in supplier diversity spend
from FY 2020, across all categories of diverse-owned businesses and
small business suppliers.
- Healthy workforce and communities – The company's FY
2021 global pay equity assessment of associates in 57 countries,
showed female employees earned 98
cents for every $1 earned by
male associates (99 cents in the
U.S.), making progress toward the company's commitment to achieve
100% pay equity. [The results showed that BD associates are paid
fairly and equitably, and that on average, both women and men are
paid within a range that would be expected after controlling for
legitimate differentiating factors.] In support of community and
human health, BD donated more than $24
million in cash and products worldwide to eligible
non-profit organizations to support resilient communities and
expand healthcare access and equity. This included $4.1 million in cash and product donations in
U.S. free and charitable clinics and community centers, with such
contributions totaling $34.5 million
since 2009.
- Transparency – BD published its first Inclusion,
Diversity and Equity report and its second Cybersecurity report.
The company earned a 100% score on the 2021 corporate political
disclosure and accountability index from the Center for Political
Accountability, and it was named one of America's Most Responsible
Companies and America's Most Trusted Companies by Newsweek.
The ESG report also includes disclosures that follow the guidelines
of the October 2021 report
"Implementing the Recommendations of the Task Force on
Climate-related Financial Disclosures."
"We worked with a wide range of stakeholders to drive our
strategy and track progress over the last year, which includes
launching a Sustainable Medical Technology Institute, joining the
Race to Zero, setting science-based targets to help address the
worst effects of climate change, and increasing renewable energy
sources," said Maureen Mazurek, vice
president of Sustainability, Environment, Health and Safety and
Product Stewardship at BD. "We developed our 2030+ ESG
commitments by focusing our organization where we can make the
greatest impact on our industry, people, communities and our planet
today. We know this work can make a lasting positive impact,
which is why we will continue to challenge ourselves to find
opportunities to grow, improve and do what is right."
View the full FY 2021 Environmental, Social and Governance
Report on BD.com.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines
of health care by developing innovative technology, services
and solutions that help advance both clinical therapy for patients
and clinical process for health care providers. BD and
its 75,000 employees have a passion and commitment to help enhance
the safety and efficiency of clinicians' care delivery process,
enable laboratory scientists to accurately detect disease and
advance researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in
virtually every country and partners with organizations around the
world to address some of the most challenging global health issues.
By working in close collaboration with customers, BD
can help enhance outcomes, lower costs, increase
efficiencies, improve safety and expand access to health care. For
more information on BD, please visit bd.com
or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter
@BDandCo.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws regarding BD's
business, strategy, goals, commitments and objectives.
Forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from those
expressed, projected, anticipated or implied in such statements.
All statements, other than statements of historical facts, may be
forward-looking statements. Some forward-looking statements may be
identified by the use of words such as "plan," "expect," "believe,"
"intend," "will," "may," "anticipate," estimate," "target," and
other words of similar meaning in conjunction with, among other
things, discussions of future operations and financial performance
and strategy for growth, future product development, regulatory
approvals, competitive position, sustainability initiatives and
expenditures. Readers should not place undue reliance on
forward-looking statements. Forward-looking statements are, and
will be, based on management's then-current views and assumptions
regarding future events, developments and operating performance,
and speak only as of their dates.
Statements regarding BD's goals, commitments and objectives may
include statistics or metrics that are based on estimates and
assumptions under developing standards that may change in the
future. Such goals and commitments are not intended to be promises
or guarantees and actual results may differ, possibly materially.
It is not possible to predict or identify all of these risks and
uncertainties, many of which are beyond BD's control, including
without limitation, challenges relating to economic, competitive,
governmental, and technological factors affecting BD's operations,
markets, and products, and other factors listed in BD's 2021 Annual
Report on Form 10-K and other filings with the Securities and
Exchange Commission. BD expressly disclaims any undertaking to
update or revise any forward-looking statements set forth herein to
reflect events or circumstances after the date hereof, except as
required by applicable law or regulation.
Contacts:
|
|
Media:
|
Investors:
|
Jessica Offerjost
BD Public Relations
201.258.0964
jessica.offerjost@bd.com
|
Francesca
DeMartino
SVP, Head of Investor
Relations
201.847.5743
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-issues-2021-esg-report-301580024.html
SOURCE BD (Becton, Dickinson and Company)